Appclon-Licensed Gastric Cancer Drug Completes First Patient Dosing in Global Phase 3 Trial

On June 5, Appclon announced that the first patient dosing (FPI) has been completed for the global Phase 3 clinical trial ...
The Manila Times

World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...
Yahoo Finance

Gastric Cancer Global Clinical Trials Market Review Report 2026: Region, Country (G7 & E7), Phase, Trial Status, End Points Status and Sponsor Type

Dublin, May 11, 2026 (GLOBE NEWSWIRE)-- The "Gastric Cancer - Global Clinical Trials Review, 2026" has been added to ResearchAndMarkets.com's offering. This comprehensive report presents top-line data ...
Business Wire

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual ...